Background Disclosing financial interests to potential research participants during the informed consent process is one strategy for managing conflicts of interest. Given that clinical research coordinators are typically charged with administering the informed consent process, it is critical to understand their experiences, attitudes and beliefs regarding the disclosure of financial interests in research.
Purpose To understand the role of clinical research coordinators in disclosing financial interests in research, and potential barriers to such disclosures.
Methods We developed a survey designed to measure clinical research coordinators' awareness of financial interests in clinical research, previous experience with disclosing financial interests, comfort with answering questions about financial interests and barriers to disclosing financial interests to potential research participants. Next we conducted cognitive interviews with 10 clinical research coordinators to assess understandability and content validity and to further refine the survey. We then administered the survey to clinical research coordinators attending the 2006 Global Conference of the Association of Clinical Research Professionals.
Results Among 300 clinical research coordinators who completed the survey, there was a general awareness of financial interests in research. Forty-one percent reported disclosing such financial interests to potential research participants, and 28% reported being asked about them. Greater comfort in responding to questions about financial interests was associated with previous experience with disclosure, previous experience answering questions about financial interests, and greater length of time obtaining informed consent. Respondents indicated that there were barriers to disclosure, including lack of information (76%) and that participants would not understand disclosures (26%).
Limitations Possible sample bias due to using a convenience sample.
Conclusions Making information about financial interests in research readily available to clinical research coordinators, as well as providing education and training, should facilitate the disclosure of financial interests in research to potential research participants during the informed consent process. Clinical Trials 2007; 4: 272—278. http://ctj.sagepub.com
Get full access to this article
View all access options for this article.
References
1.
Blumenthal D.Academic-industrial relationships in the life sciences. N Engl J Med2003; 349: 2452—59.
2.
Bodenheimer T.Uneasy alliance—clinical investigators and the pharmaceutical industry. N Engl J Med2000; 342: 1539—44.
3.
Korenman SGConflicts of interest and commercialization of research. Acad Med1993; 68(9 Suppl): S18—22.
4.
Shalala D.Protecting research subjects—what must be done. N Engl J Med2000; 343: 808—10.
5.
Thompson DFUnderstanding financial conflicts of interest. N Engl J Med1993; 329: 573—76.
6.
National Bioethics Advisory Commission.Ethical and policy issues in research involving human participants: report and recommendations of the National Bioethics Advisory Commission, Vol. 1. National Bioethics Advisory Commission, 2001.
7.
Financial relationships and interests in research involving human subjects: guidance for human subject protection. Fed Regist2004; 69: 26393—97.
8.
Weinfurt KP, Friedman JY, Allsbrook JS et al. Views of potential research participants on financial conflicts of interest: barriers and opportunities for effective disclosure. J Gen Intern Med2006; 21: 901—906.
9.
Weinfurt KP, Friedman JY, Dinan MA et al. Disclosing conflicts of interest in clinical research: views of institutional review boards, conflict of interest committees, and investigators . J Law Med Ethics2006; 34: 581—91.
10.
Kim SY, Millard RW, Nisbet P., Cox C., Caine EDPotential research participants' views regarding researcher and institutional conflicts of interest. J Med Ethics2004; 30: 73—79.
11.
Roche K., Paul N., Smuck B. et al. Factors affecting workload of cancer clinical trials: results of a multicenter study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol2002; 20: 545—56.
12.
Grunfeld E. , Zitzelsberger L., Coristine M. et al. Barriers and facilitators to enrollment in cancer clinical trials: qualitative study of the perspectives of clinical research associates. Cancer2002; 95: 1577—83.
13.
Shamoo AE, Resnik DBEthical issues for clinical research managers. Drug Inf J2006; 40: 371—83.
14.
Wright JR, Crooks D., Ellis PM et al. Factors that influence the recruitment of patients to Phase III studies in oncology: the perspective of the clinical research associate . Cancer2002; 95: 1584—91.
15.
ACRP Membership.Association of Clinical Research Professionals website. Available at http://www.acrpnet.org/membership/index.html. Accessed 6 August 2006.
16.
Loh WY, Butow PN, Brown RF et al. Ethical communication in clinical trials. Issues faced by data managers in obtaining informed consent. Cancer2002; 95: 2414—21.
